David Eichten, DO
Orthopaedic Surgery · Fort Myers, FLNPI 1073718797
Payments from drug & device makers
Across 62 payments — averaging $887.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Nextstep Arthropedix, LLC$30K
- Signature Orthopaedics USA Corp$20K
- Zimmer Biomet$3K
- Arthrex$847
- Medacta USA, Inc.$168
- Smith+Nephew$153
- plus $712 from 13 others
What the payments were for
- Royalty or licence$29,55254%
- Consulting fees$20,10037%
- Travel & lodging$1,4343%
- Food & beverage$3,1166%
- Education$8352%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Nextstep Arthropedix, LLC | 3 | $30,266 |
| Signature Orthopaedics USA Corp | 1 | $20,100 |
| Zimmer Biomet | 34 | $2,792 |
| Arthrex | 2 | $847 |
| Medacta USA, Inc. | 3 | $168 |
| Smith+Nephew | 3 | $153 |
| Boston Scientific | 1 | $125 |
| Vertex | 1 | $120 |
| Alpha Orthopedic Systems | 1 | $120 |
| Heron Therapeutics, Inc. | 1 | $94 |
| DJO, LLC | 2 | $43 |
| Baxter Healthcare | 2 | $42 |
| Pacira Pharmaceuticals Incorporated | 1 | $36 |
| Avanos Medical | 2 | $30 |
| Bioventus LLC | 1 | $29 |
| MVP Orthopedics Inc | 1 | $26 |
| Ferring Pharmaceuticals Inc. | 1 | $20 |
| Endo Pharmaceuticals Inc. | 1 | $14 |
| Sanofi-aventis U.S. LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$55,037 in reported general payments places this provider in the 80th percentile of 1,263 orthopaedic surgery providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Celecoxib | 117 | $2,562 |
| Cephalexin | 223 | $1,591 |
| Cefadroxil | 114 | $852 |
| Oxycodone Hcl | 110 | $703 |
| Mupirocin | 116 | $671 |
| Gabapentin | 134 | $520 |
| Methylprednisolone | 73 | $466 |
| Ondansetron Hcl | 95 | $415 |
| Clindamycin Hcl | 42 | $121 |
| Doxycycline Hyclate | 19 | $109 |
| Hydromorphone Hcl | 15 | $92 |
| Meloxicam | 53 | $76 |
| Ondansetron OdtOndansetron | 15 | $72 |
| Tramadol Hcl | 11 | $42 |
Paid to pharmacies, not to this prescriber.
Other orthopaedic surgery in Fort Myers
- William HodgeFort Myers$1.1M
- Andrew CooperClearwater$102M
- Richard HynesMelbourne$35M
- Mark FrankleTemple Terrace$31.4M
- David WatsonTemple Terrace$21M
- Roy SandersTemple Terrace$19.6M
- George HaidukewychOrlando$10M
- Martin RocheFt. Lauderdale$7.3M
- Robert SantrockFernandina Beach$7.3M
- Steven LyonsTampa$6.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.